兽用生物标记市场－全球产业规模、份额、趋势、机会及预测：按动物类型、产品类型、应用、疾病类型、地区和竞争格局划分，2021-2031年

全球兽医生物标记市场预计将从 2025 年的 11.1 亿美元成长到 2031 年的 23.1 亿美元，复合年增长率为 12.99%。

兽医生物标记是指能够指示动物正常生物过程、病理变化或药物治疗反应的生物分子、基因或特定特征。市场成长的主要驱动力是动物慢性病发病率的上升，以及肿瘤学和心臟病学等领域对精准、非侵入性诊断日益增长的需求。伴侣动物数量的显着增长进一步强化了这一上升趋势，催生了对专业健康监测解决方案的需求。例如，欧洲宠物食品工业联合会 (FEDIAF) 报告称，到 2024 年，“将有 9,100 万欧洲家庭至少拥有一隻宠物”，这凸显了庞大的消费群对早期疾病检测能力的需求。

儘管存在这些积极因素，但由于生物标记检验和商业化成本高昂，市场仍面临许多障碍。这些高成本通常会导致诊断测试价格上涨，对发展中地区的宠物饲主和小规模兽医诊所带来沉重的财务负担。因此，这些经济因素阻碍了诊断工具的广泛应用，并限制了其进入整个市场。

市场驱动因素

兽医保健成本的显着增长是加速采用先进生物标记解决方案的主要因素。随着饲主越来越将宠物视为家庭成员，他们也越来越愿意为高品质的医疗保健服务付费，包括心臟病和癌症等慢性疾病的复杂诊断检测。这种经济上的准备使得兽医诊所能够将昂贵的生物标记检测纳入常规诊疗流程，使其从专业的科研工具转变为关键的临床资源。根据美国宠物用品协会于2025年6月发布的《2024年犬猫报告》，预计到2024年，美国宠物产业的总支出将达到1,520亿美元，显示该产业拥有庞大的资金基础。这种购买力的提升直接支持了新型生物标记检测组合的商业性永续性，并使饲主更容易获得疾病的早期检测。

此外，诊断生物标记分析技术的进步是推动这一趋势的第二个主要因素，它使得在诊疗现场进行快速、精准的疾病分析成为可能。分子诊断技术和免疫检测平台的发展简化了特定生物标记的识别，使兽医能够即时实施循证治疗策略，而无需完全依赖外部实验室。这一转变体现在将这些创新商业化的主要企业的财务成功上。例如，IDEXX Laboratories 于 2025 年 2 月公布了其 2024 财年第四季和全年财务业绩，总收入达到 38.98 亿美元，这主要得益于对诊断工具的稳定需求。此外，市场机会不仅限于北美。正如英国宠物食品公司 (UK Pet Food) 在 2024 年指出的那样，英国有 1,720 万户家庭饲养宠物，为这些先进的诊断技术创造了庞大的欧洲市场。

市场挑战

生物标记检验和商业化所需的高昂资金负担是全球兽医生物标记市场发展的主要阻碍因素。生产商在研发和监管核可阶段被迫承担高额成本，迫使他们采取高价策略以确保投资回报。这种定价结构最终会转嫁给终端消费者，导致诊断测试的价格往往过高，难以满足标准的临床应用需求。因此，兽医往往不愿意提案可能超出客户经济承受能力的诊断方法，阻碍了这些高精度工具的广泛应用。

这些经济壁垒限制了市场成长，因为先进的生物标记仅限于富裕的宠物饲主和专业转诊中心使用，无法成为普通兽医护理的常规做法。如果目标消费族群无法承担这些高昂的价格，市场规模将难以扩大。根据美国宠物用品协会的数据，到2024年，美国兽医医疗总支出和产品销售额将达到398亿美元。目前的支出水准凸显了宠物饲主已经承受的巨大经济负担，这使得将更昂贵的诊断方案推向市场变得更加困难。

市场趋势

兽医液态生物检体解决方案的兴起正在革新肿瘤学领域，它能够非侵入性地识别循环肿瘤核小体和DNA。这项技术满足了市场对简单易用的筛检设备的重要需求，这些设备能够检测血管肉瘤和淋巴瘤等常见癌症，从而避免进行复杂且有创的组织切片检查。随着兽医将这些创新检测方法纳入早期疾病监测的常规流程，其商业性应用正在加速。例如，VolitionRx Limited在2025年3月发布的2024年全年财务报告中指出，该公司在2024年售出了约12万份Nu.Q Vet癌症检测产品，这表明基于血液的癌症筛检方法在临床应用方面取得了显着增长。

同时，预防性健康管理和筛检计画的扩展正将市场重点从被动治疗转向主动健康维护。兽医诊所越来越多地将生物标记检测纳入无症状动物的常规健康检查中，力求在症状出现之前识别潜在的心臟或肾臟问题。这种策略转变推动了每次就诊的诊断检测频率增加，而这些检测并非仅限于疾病咨询。近期的数据也证实了预防性检测的增加。 IDEXX Laboratories 在 2024 年 8 月举行的「2024 财年第二季财报电话会议」中报告称，与上年同期相比，每次健康检查的诊断频率提高了 100 个基点，凸显了预防性筛检措施已有效融入日常兽医实践中。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章：全球兽医生物标记市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 动物类型（伴侣动物、繁殖动物）
  • 依产品类型（生物标记、试剂盒和试剂、生物标记读取器）
  • 按应用领域（疾病诊断、临床前研究等）
  • 依疾病类型（发炎/感染疾病、心血管疾病、骨骼肌疾病、肿瘤、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美兽医生物标记市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲兽医生物标记市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区兽医生物标记市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲兽医生物标记市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲兽医生物标记市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球兽医生物标记市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Zoetis Inc.
• Virbac SA
• Life Diagnostics Inc
• INGENIUS BIOTECH SL
• Merck & Co., Inc.
• IDEXX Laboratories, Inc.
• Mercodia AB
• Antech Diagnostics Inc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Veterinary Biomarkers Market is projected to expand from USD 1.11 Billion in 2025 to USD 2.31 Billion by 2031, reflecting a compound annual growth rate of 12.99%. Veterinary biomarkers, defined as biological molecules, genes, or specific characteristics, function as indicators of normal biological processes, pathogenic changes, or responses to pharmacological treatments in animals. The market's growth is largely fueled by the increasing incidence of chronic diseases in animals and a growing need for precise, non-invasive diagnostics in fields such as oncology and cardiology. This upward trend is reinforced by the significant rise in the companion animal population, creating a demand for specialized health monitoring solutions. For example, 'FEDIAF' reported in '2024' that '91 million European households owned at least one pet', highlighting the extensive consumer base driving the need for early disease detection capabilities.

Despite these positive drivers, the market faces considerable obstacles due to the substantial costs involved in validating and commercializing biomarkers. These high expenses typically result in costly diagnostic tests, which can be financially burdensome for pet owners and smaller veterinary clinics in developing regions. Consequently, these economic factors limit the broad adoption of such diagnostic tools and restrict overall market accessibility.

Market Driver

The marked increase in veterinary healthcare spending serves as a key accelerator for the adoption of sophisticated biomarker solutions. As owners increasingly treat their pets as family members, there is a heightened willingness to pay for premium medical services, including intricate diagnostic tests for chronic ailments such as cardiac disease and cancer. This financial readiness enables veterinary clinics to incorporate expensive biomarker assays into standard practice, elevating them from specialized research instruments to vital clinical resources. Citing the American Pet Products Association's '2024 Dog and Cat Report' from June 2025, total U.S. pet industry spending hit $152 billion in 2024, demonstrating the immense financial backing of this sector. This enhanced purchasing power directly supports the commercial sustainability of new biomarker panels, facilitating broader access to early disease detection for animal owners.

Additionally, technological progress in diagnostic biomarker analysis acts as a secondary major driver, facilitating swift and precise disease profiling at the point of care. Developments in molecular diagnostics and immunoassay platforms have simplified the identification of specific biological markers, permitting veterinarians to implement real-time, evidence-based treatment strategies without total dependence on external labs. This transition is reflected in the financial success of leading companies commercializing these innovations. For example, Idexx Laboratories announced in February 2025, within their 'Fourth Quarter and Full Year 2024 Results', a total revenue of $3.898 billion, fueled by consistent demand for diagnostic tools. Moreover, the market opportunity reaches beyond North America; as noted by UK Pet Food in 2024, 17.2 million UK households owned a pet, establishing a significant European audience for these advanced diagnostic technologies.

Market Challenge

The heavy financial load required for biomarker validation and commercialization acts as a major constraint on the Global Veterinary Biomarkers Market. Producers face high costs during research and regulatory approval stages, forcing them to adopt premium pricing strategies to secure a return on investment. This pricing structure is passed on to the end-user, leading to diagnostic tests that are frequently too costly for standard clinical use. As a result, the uptake of these high-precision tools is hindered, as veterinarians often hesitate to suggest diagnostics that might surpass their clients' financial limits.

Such economic barriers restrict market growth by limiting the use of advanced biomarkers to wealthy pet owners or specialized referral hospitals, preventing them from becoming standard practice in general veterinary care. The market faces difficulty scaling when the intended consumer base is unable to afford these premium prices. Data from the 'American Pet Products Association' indicates that in '2024', 'spending on veterinary care and product sales in the U.S. totaled $39.8 billion'. This level of current spending highlights the substantial financial burden already placed on pet owners, making it difficult to introduce further expensive diagnostic options into the market.

Market Trends

The rise of Veterinary Liquid Biopsy Solutions is revolutionizing the oncology landscape by allowing for the non-invasive identification of circulating tumor nucleosomes and DNA. This development meets a vital market demand for straightforward, accessible screening instruments capable of detecting common cancers like hemangiosarcoma and lymphoma, bypassing the need for complex invasive tissue biopsies. The commercial uptake of these innovative assays is gaining speed as veterinarians incorporate them into standard routines for early disease surveillance. For example, VolitionRx Limited reported in March 2025, within their 'Full Fiscal Year 2024 Financial Results', sales of roughly 120,000 Nu.Q Vet Cancer Tests in 2024, indicating a marked rise in the clinical application of blood-based cancer screening methods.

Concurrently, the growth of Preventive Wellness and Screening Programs is moving the market focus from reactive treatment to proactive health maintenance. Veterinary clinics are increasingly including biomarker panels in standard wellness check-ups for asymptomatic animals, seeking to identify sub-clinical cardiac or renal issues before symptoms appear. This strategic shift is increasing diagnostic usage rates per visit, separate from appointments for illness. Evidence of this rise in proactive testing is seen in recent data; Idexx Laboratories noted in their 'Q2 Fiscal Year 2024 Earnings Call' in August 2024 that diagnostic frequency per wellness visit grew by 100 basis points year-over-year, highlighting the successful incorporation of preventive screening measures into routine veterinary practice.

Key Market Players

• Zoetis Inc.
• Virbac SA
• Life Diagnostics Inc
• INGENIUS BIOTECH SL
• Merck & Co., Inc.
• IDEXX Laboratories, Inc.
• Mercodia AB
• Antech Diagnostics Inc

Report Scope

In this report, the Global Veterinary Biomarkers Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Veterinary Biomarkers Market, By Animal Type

• Companion Animals
• Production Animals

Veterinary Biomarkers Market, By Product Type

• Biomarkers
• Kits & Reagents
• Biomarker Readers

Veterinary Biomarkers Market, By Application

• Disease Diagnostics
• Preclinical Research
• Others

Veterinary Biomarkers Market, By Disease Type

• Inflammatory & Infectious Diseases
• Cardiovascular Diseases
• Skeletal Muscle Diseases
• Tumor
• Others

Veterinary Biomarkers Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Veterinary Biomarkers Market.

Available Customizations:

Global Veterinary Biomarkers Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Veterinary Biomarkers Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Animal Type (Companion Animals, Production Animals)
  • 5.2.2. By Product Type (Biomarkers, Kits & Reagents, Biomarker Readers)
  • 5.2.3. By Application (Disease Diagnostics, Preclinical Research, Others)
  • 5.2.4. By Disease Type (Inflammatory & Infectious Diseases, Cardiovascular Diseases, Skeletal Muscle Diseases, Tumor, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Veterinary Biomarkers Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Animal Type
  • 6.2.2. By Product Type
  • 6.2.3. By Application
  • 6.2.4. By Disease Type
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Veterinary Biomarkers Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Animal Type
      • 6.3.1.2.2. By Product Type
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By Disease Type
  • 6.3.2. Canada Veterinary Biomarkers Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Animal Type
      • 6.3.2.2.2. By Product Type
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By Disease Type
  • 6.3.3. Mexico Veterinary Biomarkers Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Animal Type
      • 6.3.3.2.2. By Product Type
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By Disease Type

7. Europe Veterinary Biomarkers Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Animal Type
  • 7.2.2. By Product Type
  • 7.2.3. By Application
  • 7.2.4. By Disease Type
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Veterinary Biomarkers Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Animal Type
      • 7.3.1.2.2. By Product Type
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By Disease Type
  • 7.3.2. France Veterinary Biomarkers Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Animal Type
      • 7.3.2.2.2. By Product Type
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By Disease Type
  • 7.3.3. United Kingdom Veterinary Biomarkers Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Animal Type
      • 7.3.3.2.2. By Product Type
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By Disease Type
  • 7.3.4. Italy Veterinary Biomarkers Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Animal Type
      • 7.3.4.2.2. By Product Type
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By Disease Type
  • 7.3.5. Spain Veterinary Biomarkers Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Animal Type
      • 7.3.5.2.2. By Product Type
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By Disease Type

8. Asia Pacific Veterinary Biomarkers Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Animal Type
  • 8.2.2. By Product Type
  • 8.2.3. By Application
  • 8.2.4. By Disease Type
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Veterinary Biomarkers Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Animal Type
      • 8.3.1.2.2. By Product Type
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By Disease Type
  • 8.3.2. India Veterinary Biomarkers Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Animal Type
      • 8.3.2.2.2. By Product Type
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By Disease Type
  • 8.3.3. Japan Veterinary Biomarkers Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Animal Type
      • 8.3.3.2.2. By Product Type
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By Disease Type
  • 8.3.4. South Korea Veterinary Biomarkers Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Animal Type
      • 8.3.4.2.2. By Product Type
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By Disease Type
  • 8.3.5. Australia Veterinary Biomarkers Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Animal Type
      • 8.3.5.2.2. By Product Type
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By Disease Type

9. Middle East & Africa Veterinary Biomarkers Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Animal Type
  • 9.2.2. By Product Type
  • 9.2.3. By Application
  • 9.2.4. By Disease Type
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Veterinary Biomarkers Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Animal Type
      • 9.3.1.2.2. By Product Type
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By Disease Type
  • 9.3.2. UAE Veterinary Biomarkers Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Animal Type
      • 9.3.2.2.2. By Product Type
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By Disease Type
  • 9.3.3. South Africa Veterinary Biomarkers Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Animal Type
      • 9.3.3.2.2. By Product Type
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By Disease Type

10. South America Veterinary Biomarkers Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Animal Type
  • 10.2.2. By Product Type
  • 10.2.3. By Application
  • 10.2.4. By Disease Type
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Veterinary Biomarkers Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Animal Type
      • 10.3.1.2.2. By Product Type
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By Disease Type
  • 10.3.2. Colombia Veterinary Biomarkers Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Animal Type
      • 10.3.2.2.2. By Product Type
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By Disease Type
  • 10.3.3. Argentina Veterinary Biomarkers Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Animal Type
      • 10.3.3.2.2. By Product Type
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By Disease Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Veterinary Biomarkers Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Zoetis Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Virbac SA
• 15.3. Life Diagnostics Inc
• 15.4. INGENIUS BIOTECH SL
• 15.5. Merck & Co., Inc.
• 15.6. IDEXX Laboratories, Inc.
• 15.7. Mercodia AB
• 15.8. Antech Diagnostics Inc

16. Strategic Recommendations

17. About Us & Disclaimer